These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 32655020)
1. Effects of Carvedilol on Cardiovascular Events and Mortality in Hemodialysis Patients, A Systematic Review and Meta-Analysis. Tan Z; Ke G; Huang J; Yang D; Pi M; Li L; Liu X; Tao S; Chen L; Liang G; Liu S Iran J Kidney Dis; 2020 Jul; 14(4):256-266. PubMed ID: 32655020 [TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of carvedilol treatment for dilated cardiomyopathy: A meta-analysis of randomized controlled trials. Li T; Yuan G; Ma C; Jin P; Zhou C; Li W Medicine (Baltimore); 2019 May; 98(18):e15403. PubMed ID: 31045794 [TBL] [Abstract][Full Text] [Related]
3. Effect of Ascorbic Acid on Mineral and Bone Disorders in Hemodialysis Patients: a Systematic Review and Meta-Analysis. Ke G; Huang J; Zhu Y; Yang J; Zhang Y; Chen L; Hu J; Tao S; Hu Y; Yang D; Liu S Kidney Blood Press Res; 2018; 43(5):1459-1471. PubMed ID: 30248670 [TBL] [Abstract][Full Text] [Related]
4. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Huang S; Zhao Q; Yang ZG; Diao KY; He Y; Shi K; Shen MT; Fu H; Guo YK Heart Fail Rev; 2019 May; 24(3):325-333. PubMed ID: 30523513 [TBL] [Abstract][Full Text] [Related]
5. Cardio-selective versus non-selective β-blockers for cardiovascular events and mortality in long-term dialysis patients: A systematic review and meta-analysis. Tao S; Huang J; Xiao J; Ke G; Fu P PLoS One; 2022; 17(12):e0279171. PubMed ID: 36534654 [TBL] [Abstract][Full Text] [Related]
6. Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials. Zhan T; Daniyal M; Li J; Mao Y Herz; 2020 Dec; 45(Suppl 1):1-14. PubMed ID: 30656389 [TBL] [Abstract][Full Text] [Related]
8. Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. Wang AY; Ninomiya T; Al-Kahwa A; Perkovic V; Gallagher MP; Hawley C; Jardine MJ Am J Kidney Dis; 2014 Jun; 63(6):968-78. PubMed ID: 24685515 [TBL] [Abstract][Full Text] [Related]
9. β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis. Zhou H; Sim JJ; Shi J; Shaw SF; Lee MS; Neyer JR; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ Am J Kidney Dis; 2021 May; 77(5):704-712. PubMed ID: 33010357 [TBL] [Abstract][Full Text] [Related]
11. Effects of Beta-Blockers on Cardiovascular Events and Mortality in Dialysis Patients: A Systematic Review and Meta-Analysis. Jin J; Guo X; Yu Q Blood Purif; 2019; 48(1):51-59. PubMed ID: 31039562 [TBL] [Abstract][Full Text] [Related]
12. Timing of dialysis initiation, duration and frequency of hemodialysis sessions, and membrane flux: a systematic review for a KDOQI clinical practice guideline. Slinin Y; Greer N; Ishani A; MacDonald R; Olson C; Rutks I; Wilt TJ Am J Kidney Dis; 2015 Nov; 66(5):823-36. PubMed ID: 26498415 [TBL] [Abstract][Full Text] [Related]
13. The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction. Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Lee SE; Kim JJ; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Cho MC; Park HY; Oh BH Korean J Intern Med; 2019 Sep; 34(5):1030-1039. PubMed ID: 30317846 [TBL] [Abstract][Full Text] [Related]
14. Association of triiodothyronine levels with left ventricular function, cardiovascular events, and mortality in hemodialysis patients. Gao J; Xu Y; Kong D; Zhou L; Jia H; Liang B; Gu Z Int J Artif Organs; 2017 Mar; 40(2):60-66. PubMed ID: 28315504 [TBL] [Abstract][Full Text] [Related]
15. Carvedilol: a review of its use in chronic heart failure. Keating GM; Jarvis B Drugs; 2003; 63(16):1697-741. PubMed ID: 12904089 [TBL] [Abstract][Full Text] [Related]
16. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Massie BM; Nelson JJ; Lukas MA; Greenberg B; Fowler MB; Gilbert EM; Abraham WT; Lottes SR; Franciosa JA; Am J Cardiol; 2007 May; 99(9):1263-8. PubMed ID: 17478155 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889 [TBL] [Abstract][Full Text] [Related]
18. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. Greenberg BH; Mehra M; Teerlink JR; Ordronneau P; McCollum D; Gilbert EM Am J Cardiol; 2006 Oct; 98(7A):53L-59L. PubMed ID: 17023233 [TBL] [Abstract][Full Text] [Related]
19. Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis. Zhao Y; Yan B; Zhao Z; Wang S; Weng X Ren Fail; 2016; 38(4):589-99. PubMed ID: 26905224 [TBL] [Abstract][Full Text] [Related]
20. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial). Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]